Clinical Trial: Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational

Official Title: Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.

Brief Summary: Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.

Detailed Summary: Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.
Sponsor: LEO Pharma

Current Primary Outcome:

• Actinic keratosis [ Time Frame: 8 weeks ]
  Documentation of the course of actinic keratoses and skin findings during ambulant routine use of Picato®
• Quality of life [ Time Frame: 8 weeks ]
  Patient' s quality of life during ambulant routine use of Picato®
• Dosage of Picato® [ Time Frame: 8 weeks ]
  Prescribed and applied dosages and adherence during ambulant routine use of Picato®

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: LEO Pharma

Dates:
Date Received: March 12, 2014
Date Started: July 2013
Date Completion: April 2014
Last Updated: March 17, 2014
Last Verified: March 2014